|
2011 Conference Publication Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre studyMorel-Kopp, MC, Tan, CW, Brighton, T, McRae, S, Tran, H, Mollee, P, Kershaw, G, Joseph, J, Coyle, L and Ward, C (2011). Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study. Unknown, unknown, unknown. HOBOKEN: WILEY-BLACKWELL. |
|
2010 Conference Publication Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosisMollee, P., Tate, J., Weiss, D. and Solomon, A. (2010). Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome, Italy, 18-21, April 2010. London, United Kingdom: Informa Healthcare. |
|
2010 Conference Publication Survival and prognostic factors amongst Australian patients with AL amyloidosisMollee, P, Tate, J, Morris, K, Wellwood, J, Browne, M, Marlton, P, Bird, R, Mills, AK, Wood, P, Mapp, S and Gill, D (2010). Survival and prognostic factors amongst Australian patients with AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome Italy, Apr 18-21, 2010. LONDON: INFORMA HEALTHCARE. |
|
2010 Conference Publication WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidationGray, James X., McMillen, Lyle, Saal, Russell, Lane, Steven, Bird, Robert, Gill, Devinder, Mollee, Peter and Marlton, Paula (2010). WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation. Royal College of Pathologists of Australasia Pathology Update, Melbourne, VIC Australia, 26-28 February 2010. Oxford, United Kingdom: Elsevier. doi: 10.1097/01268031-201042001-00118 |
|
2009 Conference Publication WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)Gray, James X, McMillen, Lyle, Saal, Russell, Lane, Steven, Mollee, Peter, Bird, Robert, Gill, Devinder and Marlton, Paula (2009). WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML). 51st ASH Annual Meeting, New Orleans, LA, 5-8 December 2009. American Society of Hematology. doi: 10.1182/blood.v114.22.2639.2639 |
|
2009 Conference Publication Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort studyMollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. 51st ASH Annual Meeting, New Orleans, LA United States, 5–8 December 2009. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v114.22.1382.1382 |
|
2009 Conference Publication WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)Gray, J. X., McMillen, L., Saal, R., Lane, S., Mollee, P., Bird, R., Gill, D. and Marlton, P. (2009). WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML). 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5-8 December 2009. Washington, DC, United States: American Society of Hematology. |
|
2009 Conference Publication Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort studyMollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. 51st ASH Annual Meeting and Exposition, New Orleans, LA, U.S.A., 5-8 December 2009. Washington, DC, U.S.A.: American Society of Hematology. |
|
2009 Conference Publication Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trialTrappe, Ralf, Choquet, Sylvain, Oertel, Stephan H.K., Leblond, Veronique, Dierickx, Daan, Mollee, Peter, Sender, Monica, Ekman, Tor, Zaucha, Jan Maciej, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Dreyling, Martin H., Duhrsen, Ulrich, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Anagnostopoulos, Ioannis, Raphael, Martine, Dorken, Bernd and Riess, Hanno (2009). Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5 - 8 December 2009. Washington, DC, United States: American Society of Hematology. |
|
2008 Conference Publication Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) populationKeane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014 |
|
2008 Conference Publication Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitroGill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.3157.3157 |
|
2008 Conference Publication Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitroGill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th Annual Meeting of the American- Society-of-Hematology, San Francisco, CA, United States, 6 - 9 December 2008. Washington, DC, United States: American Society of Hematology. |
|
2008 Conference Publication Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlationsTate, J.R., Bazeley, S., Sykes, S. and Mollee, P. (2008). Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations. 60th Annual Meeting of the American Association for Clinical Chemistry, Washington, DC, United States, 27-31 July 2008. Washington, DC, United States: American Association for Clinical Chemistry. |
|
2007 Conference Publication JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)Weston, Helen, Bird, Robert, Griffiths, Vanessa, Jones, Mark, Grimmett, Karen, Saal, Russell, Mills, Anthony K., Gill, Devinder, Marlton, Paula and Mollee, Peter (2007). JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2007. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v110.11.2551.2551 |
|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsMollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology. |
|
2007 Conference Publication JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)Weston, H, Bird, R, Griffiths, V, Jones, M, Grimmett, K, Saal, R, Mills, AK, Gill, D, Marlton, P and Mollee, P (2007). JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 08-11, 2007. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant PatientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II studyTrappe, R., Choquet, S., Oertel, S., LeBlond, V., Ekman, T., Sender, M., Mollee, P, Reinke, P., Lehmkuhl, H., Hummel, M., Jonas, S., Neuhaus, R., Salles, G., Morschhauser, F., Jaccard, A., Anagnostopoulos, I., Raphael, M. and Riess, H. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Annual American Transplant Congress, San Francisco, CA, United States, 5 - 9 May 2007. Malden, MA, United States: Wiley-Blackwell Publishing. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2006 Conference Publication Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patientsGill, Saar, Lane, Steven, Crawford, Julie, Mollee, Peter, Marlton, Paula, Cull, Gavin, Prince, Miles and Seymour, John Francis (2006). Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.v108.11.2441.2441 |
